Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

to connected objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
In: 10.1038/leu.2016.20

Event
Veröffentlichung
(where)
Aachen
(who)
Universitätsbibliothek der RWTH Aachen
(when)
2016
Creator
Miranda, M. B.
Lauseker, M.
Kraus, M.-P.
Proetel, U.
Hanfstein, B.
Fabarius, A.
Baerlocher, G. M.
Heim, D.
Hossfeld, D. K.
Kolb, H.-J.
Krause, S. W.
Nerl, C.
Brümmendorf, Tim Henrik
Verbeek, W.
Fauser, A. A.
Prümmer, O.
Neben, K.
Hess, U.
Mahlberg, R.
Plöger, C.
Flasshove, M.
Rendenbach, B.
Hofmann, W.-K.
Müller, M. C.
Pfirrmann, M.
Hochhaus, A.
Hasford, J.
Hehlmann, R.
Saußele, Susanne

DOI
10.18154/RWTH-CONV-211206
URN
urn:nbn:de:101:1-2018101106082973282994
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
25.03.2025, 1:47 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Miranda, M. B.
  • Lauseker, M.
  • Kraus, M.-P.
  • Proetel, U.
  • Hanfstein, B.
  • Fabarius, A.
  • Baerlocher, G. M.
  • Heim, D.
  • Hossfeld, D. K.
  • Kolb, H.-J.
  • Krause, S. W.
  • Nerl, C.
  • Brümmendorf, Tim Henrik
  • Verbeek, W.
  • Fauser, A. A.
  • Prümmer, O.
  • Neben, K.
  • Hess, U.
  • Mahlberg, R.
  • Plöger, C.
  • Flasshove, M.
  • Rendenbach, B.
  • Hofmann, W.-K.
  • Müller, M. C.
  • Pfirrmann, M.
  • Hochhaus, A.
  • Hasford, J.
  • Hehlmann, R.
  • Saußele, Susanne
  • Universitätsbibliothek der RWTH Aachen

Time of origin

  • 2016

Other Objects (12)

Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib

Hochschulschrift

Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Quantitative diversity of lipid signatures in hematological malignancies : acute Myeloid Leukemia

Hochschulschrift

Quantitative diversity of lipid signatures in hematological malignancies : acute Myeloid Leukemia

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)

STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)

Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells

Hochschulschrift

Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells

Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells

Hochschulschrift

Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies

Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Related objects